Cansino Biologics, Inc. Class ASSE: 688185

Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis